{"disease":{"id":"myelofibrosis-primary","name":"myelofibrosis primary"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07362225","title":"MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"MPN Research Foundation","has_results":false},{"nct_id":"NCT06785870","title":"EVAluation of Erythrocytosis PRospEctive Cohort STudy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Cyrus Hsia","has_results":false},{"nct_id":"NCT06516406","title":"Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera","phase":"","overall_status":"RECRUITING","enrollment_count":1055,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT06479135","title":"Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Kartos Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04603495","title":"Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":430,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02158858","title":"A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":336,"lead_sponsor_name":"Constellation Pharmaceuticals","has_results":false},{"nct_id":"NCT04717414","title":"An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":313,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT04942080","title":"Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)","phase":"NA","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"University Hospital, Angers","has_results":false},{"nct_id":"NCT04551066","title":"To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":252,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT03441113","title":"Extended Access of Momelotinib in Adults With Myelofibrosis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":237,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT03402399","title":"Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary Myelofibrosis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":222,"lead_sponsor_name":"Assaf-Harofeh Medical Center","has_results":false},{"nct_id":"NCT04551053","title":"To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":177,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT04279847","title":"Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":140,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT03869476","title":"Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.","phase":"NA","overall_status":"COMPLETED","enrollment_count":133,"lead_sponsor_name":"University Hospital, Angers","has_results":false},{"nct_id":"NCT01787487","title":"Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04640532","title":"KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":116,"lead_sponsor_name":"Kartos Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03136185","title":"Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT06517875","title":"Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT02098161","title":"LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT06712810","title":"Q702 for the Treatment of Patients With Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06371573","title":"Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms","phase":"","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Federico II University","has_results":false},{"nct_id":"NCT03862157","title":"Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07518940","title":"ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid Leukemia","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":25,"lead_sponsor_name":"Carmen Fava","has_results":false},{"nct_id":"NCT04517851","title":"Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03065400","title":"PD-1 Inhibition in Advanced Myeloproliferative Neoplasms","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"John Mascarenhas","has_results":true},{"nct_id":"NCT02421354","title":"Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT03373877","title":"Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Samus Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03121599","title":"18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms","phase":"NA","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Hamad Medical Corporation","has_results":false},{"nct_id":"NCT03878524","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT04054245","title":"PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05582083","title":"Managed Access Program for Momelotinib in Myelofibrosis","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"GlaxoSmithKline","has_results":false}],"total":31},"guidelines":[],"source":"Drug Landscape verified database"}